The quinolone resistance-determining regions (QRDR) of gyrA, gyrB, parC, and parE of ten Mycoplasma hyopneumoniae field isolates that were either sensitive (5) or resistant (5) to the fluoroquinolones flumequine and enrofloxacin were characterized. In all five resistant isolates, one point mutation (C Ǟ A) in parC was found, resulting in an amino acid change from serine to tyrosine at position 80 (Escherichia coli numbering). For four of these isolates, this was the only mutation found. These isolates had a minimum inhibitory concentration (MIC) of enrofloxacin of 0.5 g/ml, whereas for sensitive isolates the MIC of enrofloxacin was Յ0.06 g/ml. One resistant isolate (Mh 20) had an extra mutation (C Ǟ T) in gyrA resulting in an amino acid change from alanine to valine at position 83 (E. coli numbering), leading to a further increase in the MIC of enrofloxacin (Ͼ1 g/ml). No mutations resulting in an amino acid change were detected in the QRDR of the gyrB and parE genes of the selected isolates. This is the first description of the mechanism of stepwise resistance against fluoroquinolones in M. hyopneumoniae.
INTRODUCTION

M
YCOPLASMA HYOPNEUMONIAE is a major swine pathogen causing enzootic pneumonia, a chronic respiratory disease in pigs resulting in considerable economic losses. In a previous study, 36 conducted to determine the in vitro susceptibility of M. hyopneumoniae field isolates to frequently used antimicrobials in swine, 5 out of 21 isolates were found to be less susceptible or to be resistant to flumequine and enrofloxacin. This rather high frequency was unexpected because fluoroquinolone resistance does not often occur in swine respiratory pathogens. 14, 23, 37 Fluoroquinolones are broad-spectrum antibiotics. Their use depends on the country regulations; fluoroquinolones are not allowed for use in pigs in the United States but are allowed in the European Union. 38 In Belgian pig herds, fluoroquinolones are frequently used as a prophylactic antibiotic during the suckling period, 35 mainly to prevent neonatal diarrhea. In older pigs, these antimicrobials are mainly used to treat individual animals with diarrhea, arthritis, meningitis, or respiratory symptoms.
The most frequently used fluoroquinolones in large animal veterinary medicine are flumequine and enrofloxacin.
Fluoroquinolones are known to have two enzyme targets in the bacterial cell belonging to the topoisomerases type 2, namely DNA gyrase and topoisomerase IV. The first enzyme catalyzes adenosine triphosphate (ATP)-dependent negative supercoiling of DNA; the latter enzyme is essential for chromosome segregation. 12, 18 DNA gyrase is a tetramer composed of two GyrA and two GyrB subunits. Topoisomerase IV is similarly structured and is composed of two ParC and two ParE subunits. ParC is homologous to GyrA and ParE is homologous to GyrB. The primary target for fluoroquinolones in Gram-negative bacteria is the DNA gyrase, whereas in Gram-positive bacteria, including mycoplasmas, it seems to be topoisomerase IV. 2, 4, 7, 9, 12, 13, 18, 21 However, some exceptions to this rule were found in Streptococcus pneumoniae and Mycoplasma hominis isolates for newer fluoroquinolones, such as sparfloxacin and gatifloxacin. 3, 11 For Mycoplasma gallisepticum, the preferential target of enrofloxacin is DNA gyrase. 33 In several bacteria, mutations responsible for an increase in minimum inhibitory concentration (MIC)-value were found in the subunits of these target genes. 4, 6, 38, 40, 41 In the present study, the mechanism responsible for fluoroquinolone resistance in M. hyopneumoniae field isolates 37 was determined. Therefore, the quinolone resistance-determining regions (QRDR) of gyrA, gyrB, parC, and parE were sequenced.
MATERIALS AND METHODS
M. hyopneumoniae isolates
The 10 M. hyopneumoniae field isolates selected for this study were obtained between 2000 and 2002 from slaughter pigs from 10 different Belgian farrow-to-finish pig herds and were previously used for MIC determination. 36 Isolate selection for this study was based on the MIC value: five isolates with the highest and five isolates with the lowest MIC values for flumequine and enrofloxacin were retained. The MIC values of flumequine and enrofloxacin for four isolates (Mh 4, 8, 14, and 17) were Ͼ16 g/ml and 0.5 g/ml, respectively. For isolate Mh 20, the MIC of flumequine was Ͼ16 g/ml and that of enrofloxacin Ͼ1 g/ml. The other five isolates (Mh 7, 10, 11, 15, and 19) were susceptible to flumequine (MIC Յ2 g/ml) and enrofloxacin (MIC Յ0.06 g/ml). 37 
DNA extraction and PCR amplification
The M. hyopneumoniae isolates were grown in nonselective Friis medium and subsequently centrifuged at 5,000 ϫ g for 10 min. DNA was extracted using the DNeasy Tissue kit (Qiagen, Westburg, Leusden, The Netherlands) according to the manufacturers' instructions. Without further purification, an aliquot of the supernatant containing DNA was used as a template for PCR amplification.
To sequence parts of the DNA gyrase subunits, gyrA and gyrB, and the topoisomerase subunits, parC and parE, containing the QRDR, primers were designed based on the M. hyopneumoniae genome sequence of reference strain 232. 25 Oligonucleotides MhgyrAfor (5Ј-CTKCCRGATGTCCGW-GATGG-3Ј) and MhgyrArev (5Ј-GTSGGRAARTCYGGCYC-CGG-3Ј) were used to amplify a 557-bp gyrA fragment between positions 487 and 1,043 (Escherichia coli coordinates). A 937-bp gyrB fragment between positions 1,994 and 3,437 (E. coli coordinates) was amplified with primers MhgyrBfor (5Ј-ACATTCATAACCCTGAAGGC-3Ј) and MhgyrBrev (5Ј-GTCTCTCAAAGTTGTTCCGG-3Ј). To amplify the QRDR of parC, primers MhparCfor (5Ј-ATTCAGTAATTAATTCC-CGG-3Ј) and MhparCrev (5Ј-TCTTCAAGGTAAATTT-GCTG-3Ј) were selected to amplify a 1,309-bp fragment between positions 19 and 1,313 (E. coli coordinates) and a 735-bp parE fragment between positions 1,046 and 1,765 (E. coli coordinates) was amplified using the primers MhparEfor (5Ј-ATTCTTGAATTTGTTGGGC-3Ј) and MhparErev (5Ј-CC-CAAGTCCTTTATAGCGC-3Ј). DNA amplification was performed with a DNA thermal cycler (model 9600 GeneAmp PCR system, Perkin-Elmer, Zaventem, Belgium). Each 50-l PCR mixture contained 25 l of Mastermix (Invitrogen, Belgium), 2 M for both primers, and a 2.5-l DNA sample. Water was added to a total volume of 50 l. For all amplification reactions, the same PCR running conditions were used, consisting of an initial cycle of 5 min denaturation at 94°C, followed by 35 cycles of 1 min of denaturation at 94°C, 1 min of annealing at 55°C, and 1 min of elongation at 72°C. After amplification, 5 l of amplicon was mixed with 3 l of sample buffer (50% glycerol, 1 mM Cresol Red). This mixture was electrophoresed in a 1.5% agarose gel for 75 min at 175 V in 0.5ϫ TBE (0.45 M Tris-HCl, 0.45 M boric acid, 0.01 M EDTA).
Sequencing
After purification of the PCR product with the Qiaquick PCR purification kit (Qiagen, Westburg, Leusden, The Netherlands), both strands of the PCR product were sequenced using the Big Dye Terminator v3-1 cycle sequencing kit (Applied Biosystems, Lennik, Belgium) on a ABI Prism™ 310 Genetic Analyser. The electropherograms were exported and converted to the sequence analysis software, Kodon ® (Applied Maths, Sint-Martens-Latem, Belgium). The nucleic acid sequences of the QRDR of gyrA, gyrB, parC, and parE of the susceptible M. hyopneumoniae isolates were compared with those of the isolates with a MIC of Ͼ16 g/ml and Ն0.5 g/ml for flumequine and enrofloxacin, respectively. The deduced amino acid sequences of susceptible isolate Mh 7 and resistant isolate Mh 20 were compared with the sequences of Staphylococcus aureus, Streptococcus pneumoniae, E. coli, and, to date, fully sequenced human and veterinary Mycoplasma species. The percentage of identity between the susceptible Mh 7 isolate, the other organisms and the GenBank accession numbers are listed in Table 1 .
RESULTS
PCR amplification and sequences of PCR products
Each of the selected forward and reverse primer pairs amplified one PCR product. An acquired C264A transition (E. coli numbering) was found in the parC gene of all five isolates with MIC values Ͼ16 g/ml and Ն0.5 g/ml for flumequine and enrofloxacin, respectively. This corresponds to an amino acid change from serine to tyrosine at position 80 (E. coli numbering). An additional transition was found in isolate Mh 20. The MIC of enrofloxacin for this isolate was Ͼ1 g/ml, whereas it was 0.5 g/ml for the other resistant isolates. This additional transition, C635T, was found in gyrA, resulting in an amino acid change from alanine to valine at position 83 (E. coli numbering) ( Table 2 ). In the same isolate, another substitution, T630A, was found in gyrA. However, this substitution did not result in an amino acid change. Other silent substitutions in the QRDR of gyrA were found in isolate Mh 7 (G651A) and in isolates Mh 15, 19, and 20 (G759A). In the QRDR of gyrB, silent substitutions were found in isolates Mh 4, 8, 11, 14, 17, and 20 (T2529A) and isolates Mh 10 and 19 (G2577A). No silent substitutions were found in the QRDR of parC. In the QRDR of parE, two silent substitutions were found: C315T in isolates Mh 7 and 15, and G345A in isolates Mh 7, 11, and 15. The identity for the QRDR of the four fluoroquinolone target genes at DNA level was very high for all M. hyopneumoniae isolates; 96.30%, 98.80%, 98.78%, and 97.53% for the QRDR of gyrA, gyrB, parC, and parE, respectively.
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Resistance in M. hyopneumoniae field isolates was first described in a previous study where 5 of 21 isolates were found to be resistant to flumequine and less susceptible or resistant to enrofloxacin. 36 This prevalence of fluoroquinolone resistance is higher than the resistance rate found in other bacterial swine pathogens like Streptococcus suis, 1, 23 Arcanobacterium pyogenes, 42 Pasteurella multocida, and Mannheimia haemolytica. 37 Several mechanisms for fluoroquinolone resistance have been described in different bacterial species. These include alterations in the two drug target enzymes, namely DNA gyrase and topoisomerase IV, changes in drug permeation through modifications in the outer membrane proteins, induction of active efflux systems, modifications in the peptidoglycan layer or the outer membrane proteins, 19, 28, 29 and plasmid-correlated quinolone resistance. 15, 24 Although the existence of energy-dependent efflux systems has recently been described for M. hominis, 31 acquired resistance in Mycoplasma species is usually due to alterations in the target enzymes. In the present study, the QRDRs of the four target genes gyrA, gyrB, parC, and parE were sequenced in fluoroquinolone-susceptible and -resistant M. hyopneumoniae isolates. The amino acid change at position 80 (E. coli numbering) in parC, observed in all five resistant isolates, is the most common mutation related to fluoroquinolone resistance in Gram-positive bacteria, 10, 20, 27, 39 including M. hominis. 5 For four of the M. hyopneumoniae isolates, this was the only mutation found and it resulted in at least an eight-fold increase in the MIC of flumequine and enrofloxacin. Such isolates are considered to be resistant to flumequine (MIC Ͼ16 g/ml), 14 whereas they are still considered to be susceptible to enrofloxacin (MIC ϭ 0.5 g/ml). 26 
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a Amino acid position according to E. coli numbering.
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In a recent study, M. hyopneumoniae clones with an eightfold increase in MIC values of enrofloxacin were reisolated from pigs that had been treated with marbofloxacin after experimental infection with M. hyopneumoniae. 22 In these clones a point mutation in parC was detected, resulting in amino acid changes at positions 80, 84, or 116. Our study demonstrates that mutations in parC, resulting in amino acid changes, also occur under field conditions, warranting further monitoring of fluoroquinolone resistance in porcine Mycoplasma species. Mycoplasma hyosynoviae and Mycoplasma hyorhinis, two other pathogenic mycoplasmas in swine, also appeared to exhibit a high resistance rate against flumequine (100% and 85% resistance, respectively), although they were found to be fully susceptible to enrofloxacin. 14 The occurrence of low-level resistance against fluoroquinolones after a single mutation in parC has been described earlier for Enterococcus faecalis, S. aureus, and S. pneumoniae, whereas high-level resistant isolates had mutations in both parC and gyrA. 8, 20, 30, 34 In M. bovirhinis, however, a single mutation in parC (position 80) resulted in different MIC profiles, including low-and high-level resistant isolates. 16 The authors suggested that the differences in MIC might have been caused by the level of expression of the quinolone efflux transporter.
One isolate, Mh 20, had an extra mutation (C Ǟ T) in gyrA at position 635, resulting in an amino acid change from alanine to valine at position 83 (E. coli numbering), another hot spot for fluoroquinolone resistance. 17 This was associated with at least a four-fold increase in MIC of enrofloxacin (MIC Ͼ1 g/ml) compared to isolates with only a mutation in parC and demonstrates stepwise resistance development against fluoroquinolones in M. hyopneumoniae for the first time.
As in fluoroquinolone-resistant M. hominis, Ureaplasma urealyticum, and Acholeplasma laidlawii isolates, no mutations were found in the QRDR of gyrB in M. hyopneumoniae. Such mutations have been described in in vitro-selected resistant M. gallisepticum isolates. 32 Also, no mutations resulting in amino acid changes were found in the QRDR of parE of the M. hyopneumoniae isolates. In clinical isolates of M. hominis, however, a mutation resulting in an amino acid substitution in parE was previously observed. 6 The absence of amino acid changes in GyrB and ParE of fluoroquinolone-resistant M. hyopneumoniae isolates is in agreement with other studies reporting that amino acid changes in GyrB or ParE occur less frequently than in GyrA and ParC. 17 In conclusion, topoisomerase IV of M. hyopneumoniae seems to be the primary target for fluoroquinolones (flumequine and enrofloxacin), with position 80 in parC as the hot spot. A single mutation in parC is sufficient to reach resistance to flumequine, whereas a second mutation in the secondary target, DNA gyrase (gyrA), is necessary to make M. hyopneumoniae resistant to enrofloxacin.
